Literature DB >> 27108803

Genome-wide identification of human- and primate-specific core promoter short tandem repeats.

A Bushehri1, M R Mashhoudi Barez2, S K Mansouri3, A Biglarian4, M Ohadi5.   

Abstract

Recent reports of a link between human- and primate-specific genetic factors and human/primate-specific characteristics and diseases necessitate genome-wide identification of those factors. We have previously reported core promoter short tandem repeats (STRs) of extreme length (≥6-repeats) that have expanded exceptionally in primates vs. non-primates, and may have a function in adaptive evolution. In the study reported here, we extended our study to the human STRs of ≥3-repeats in the category of penta and hexaucleotide STRs, across the entire human protein coding gene core promoters, and analyzed their status in several superorders and orders of vertebrates, using the Ensembl database. The ConSite software was used to identify the transcription factor (TF) sets binding to those STRs. STR specificity was observed at different levels of human and non-human primate (NHP) evolution. 73% of the pentanucleotide STRs and 68% of the hexanucleotide STRs were found to be specific to human and NHPs. AP-2alpha, Sp1, and MZF were the predominantly selected TFs (90%) binding to the human-specific STRs. Furthermore, the number of TF sets binding to a given STR was found to be a selection factor for that STR. Our findings indicate that selected STRs, the cognate binding TFs, and the number of TF set binding to those STRs function as switch codes at different levels of human and NHP evolution and speciation.
Copyright © 2016 Elsevier B.V. All rights reserved.

Entities:  

Keywords:  AP-2alpha; Core promoter; Genome-wide; Human-specific; MZF; Primate-specific; Short tandem repeat; Sp1

Mesh:

Year:  2016        PMID: 27108803     DOI: 10.1016/j.gene.2016.04.041

Source DB:  PubMed          Journal:  Gene        ISSN: 0378-1119            Impact factor:   3.688


  7 in total

1.  Predominant monomorphism of the RIT2 and GPM6B exceptionally long GA blocks in human and enriched divergent alleles in the disease compartment.

Authors:  S Khamse; M Arabfard; M Salesi; E Behmard; Z Jafarian; H Afshar; M Khazaei; M Ohadi
Journal:  Genetica       Date:  2022-01-05       Impact factor: 1.082

2.  Genome-scale portrait and evolutionary significance of human-specific core promoter tri- and tetranucleotide short tandem repeats.

Authors:  N Nazaripanah; F Adelirad; A Delbari; R Sahaf; T Abbasi-Asl; M Ohadi
Journal:  Hum Genomics       Date:  2018-04-05       Impact factor: 4.639

3.  LincRNA-Gm4419 knockdown ameliorates NF-κB/NLRP3 inflammasome-mediated inflammation in diabetic nephropathy.

Authors:  Hong Yi; Rui Peng; Lu-Yu Zhang; Yan Sun; Hui-Min Peng; Han-Deng Liu; Li-Juan Yu; Ai-Ling Li; Ya-Juan Zhang; Wen-Hao Jiang; Zheng Zhang
Journal:  Cell Death Dis       Date:  2017-02-02       Impact factor: 8.469

4.  Suppression of lncRNA NLRP3 inhibits NLRP3-triggered inflammatory responses in early acute lung injury.

Authors:  Deqiang Luo; Wei Dai; Xiaojin Feng; Chengzhi Ding; Qiang Shao; Rui Xiao; Ning Zhao; Wei Peng; Ying Yang; Yamei Cui; Fen Liu; Kejian Qian
Journal:  Cell Death Dis       Date:  2021-10-01       Impact factor: 8.469

5.  Natural selection at the RASGEF1C (GGC) repeat in human and divergent genotypes in late-onset neurocognitive disorder.

Authors:  Z Jafarian; S Khamse; H Afshar; H R Khorram Khorshid; A Delbari; M Ohadi
Journal:  Sci Rep       Date:  2021-09-28       Impact factor: 4.996

6.  Transcriptional Interference Regulates the Evolutionary Development of Speech.

Authors:  Douglas P Mortlock; Zhi-Ming Fang; Kelly J Chandler; Yue Hou; Lissett R Bickford; Charles E de Bock; Valsamma Eapen; Raymond A Clarke
Journal:  Genes (Basel)       Date:  2022-07-04       Impact factor: 4.141

7.  Link between short tandem repeats and translation initiation site selection.

Authors:  Masoud Arabfard; Kaveh Kavousi; Ahmad Delbari; Mina Ohadi
Journal:  Hum Genomics       Date:  2018-10-29       Impact factor: 4.639

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.